Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

Autor: Silvia García Adrián, Adán Rodríguez González, Eva Martínez de Castro, Vanessa Pachón Olmos, Laura Ortega Morán, Purificación Martínez del Prado, Mercedes Salgado Fernández, José David Cumplido Burón, Ignacio García Escobar, Joaquina Martínez Galán, Ana Isabel Ferrer Pérez, Fernando Neria, Diego Cacho Lavin, Borja López de San Vicente Hernández, Paula Jiménez-Fonseca, Andrés J. Muñoz Martín
Rok vydání: 2022
Předmět:
Zdroj: European Journal of Internal Medicine. 105:30-37
ISSN: 0953-6205
DOI: 10.1016/j.ejim.2022.07.020
Popis: Background Pancreatic carcinoma is one of the tumors associated with a higher risk for thromboembolic events, with incidence rates ranging from 5% to 41% in previous retrospective series. Patients and methods We conducted a retrospective study in eleven Spanish hospitals that included 666 patients diagnosed with pancreatic carcinoma (any stage) between 2008 and 2011 and treated with chemotherapy. The main objective was to evaluate the incidence of venous thromboembolic events (VTE) in this population, as well as potential risk factors for thrombosis. The impact of VTE on mortality was also assessed. Results With a median follow-up of 9.3 months, the incidence of VTE was 22.1%; 52% were diagnosed incidentally. Our study was unable to confirm the ability of the Khorana score to discriminate between patients in the intermediate or high risk category for thrombosis. The presence of VTE proved to be an independent prognostic factor associated with increased risk of death (HR 2.39, 95% CI 1.96–2.92). Symptomatic events correlated with higher mortality than asymptomatic events (HR 1.72; 95% CI, 1.21–2.45; p = 0.002), but incidental VTE, including visceral vein thrombosis (VVT), negatively affected survival compared to patients without VTE. Subjects who developed VTE within the first 3 months of diagnosis of pancreatic carcinoma had lower survival rates than those with VTE after 3 months (HR 1.92, 95% CI 1.30–2.84; p
Databáze: OpenAIRE
Externí odkaz: